First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial
- PMID: 21646602
- DOI: 10.1200/JCO.2010.31.4187
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial
Abstract
Purpose: Primary testicular lymphoma (PTL) has poor prognosis with failures in contralateral testis, CNS, and extranodal sites. To prevent these events, we designed an international phase II trial (International Extranodal Lymphoma Study Group 10 [IELSG-10]) that addressed feasibility and activity of conventional chemoimmunotherapy associated with CNS prophylaxis and contralateral testis irradiation. The trial was conducted by the IELSG and the Italian Lymphoma Foundation.
Patients and methods: Fifty-three patients (age 22 to 79 years) with untreated stage I or II PTL were treated with six to eight courses of rituximab added to cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 21 days (R-CHOP21); four doses of intrathecal methotrexate (IT-MTX) and radiotherapy (RT) to the contralateral testis (30 Gy) for all patients and to regional lymph nodes (30 to 36 Gy) for stage II disease.
Results: All patients received R-CHOP21, 50 received CNS prophylaxis, and 47 received testicular RT. With a median follow-up of 65 months, 5-year progression-free survival and overall survival rates were 74% (95% CI, 59% to 84%) and 85% (95% CI, 71% to 92%), respectively. Ten patients relapsed or progressed: two in lymph nodes, five in extranodal organs, and three in the CNS. The 5-year cumulative incidence of CNS relapse was 6% (95% CI, 0% to 12%). No contralateral testis relapses occurred. Ten patients died: lymphoma (n = 6), secondary leukemia (n = 2), heart failure (n = 1), and gastric cancer (n = 1). Grade 3 to 4 toxicities were neutropenia, 28%; infections, 4%; and neurologic, 13%. No deaths occurred as a result of toxicity.
Conclusion: This international prospective trial shows that combined treatment with R-CHOP21, IT-MTX, and testicular RT was associated with a good outcome in patients with PTL. RT avoided contralateral testis relapses, but CNS prophylaxis deserves further investigation.
Comment in
-
Re: First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.J Urol. 2012 Jul;188(1):115-6. doi: 10.1016/j.juro.2012.03.060. Epub 2012 May 12. J Urol. 2012. PMID: 22682831 No abstract available.
Similar articles
-
Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.Br J Haematol. 2012 Oct;159(1):39-49. doi: 10.1111/j.1365-2141.2012.09247.x. Epub 2012 Jul 31. Br J Haematol. 2012. PMID: 22849793 Review.
-
Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.Ann Hematol. 2011 Jul;90(7):809-18. doi: 10.1007/s00277-010-1150-7. Epub 2011 Jan 13. Ann Hematol. 2011. PMID: 21229246
-
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.Cancer. 2012 Jun 1;118(11):2944-51. doi: 10.1002/cncr.26588. Epub 2011 Oct 17. Cancer. 2012. PMID: 22006274
-
Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.Cancer. 2010 Sep 15;116(18):4283-90. doi: 10.1002/cncr.25278. Cancer. 2010. PMID: 20564149
-
Contralateral testicular relapse after prophylactic radiation in a patient with primary testicular diffuse large B-cell lymphoma.Eur J Haematol. 2009 Dec 1;83(6):603-5. doi: 10.1111/j.1600-0609.2009.01327.x. Epub 2009 Aug 4. Eur J Haematol. 2009. PMID: 19682312 Review.
Cited by
-
Next-generation sequencing of primary testicular lymphoma and relapse in the glans penis after prophylactic radiation therapy: a rare case report.Diagn Pathol. 2024 Jun 3;19(1):72. doi: 10.1186/s13000-024-01498-x. Diagn Pathol. 2024. PMID: 38831436 Free PMC article.
-
Epidemiological features and a survival nomogram for primary lymphoma of the male genital tract.Ann Hematol. 2024 May;103(5):1687-1695. doi: 10.1007/s00277-024-05668-1. Epub 2024 Mar 1. Ann Hematol. 2024. PMID: 38424302
-
Successful treatment of isolated central nervous system recurrence of primary testicular lymphoma by autologous stem cell transplantation using a conditioning regimen of thiotepa and busulfan.J Clin Exp Hematop. 2024 Mar 28;64(1):32-36. doi: 10.3960/jslrt.23039. Epub 2024 Feb 28. J Clin Exp Hematop. 2024. PMID: 38417873 Free PMC article.
-
Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy - a supplementary analysis of JCOG0601.Ann Hematol. 2024 Jun;103(6):2021-2031. doi: 10.1007/s00277-024-05620-3. Epub 2024 Jan 27. Ann Hematol. 2024. PMID: 38280061 Free PMC article. Clinical Trial.
-
Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse.Int J Hematol. 2024 Feb;119(2):164-172. doi: 10.1007/s12185-023-03700-0. Epub 2024 Jan 17. Int J Hematol. 2024. PMID: 38233702
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials